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 ABSTRACT 
Sepsis has very high morbidity and mortality, which leads to major 
healthcare burden in the world. Though there is far advancement in the 
therapeutic options, the mortality rate remains high due to the delay in the 
diagnosis because of lack of availability of reliable diagnostic methods. 
In sepsis there is potent activation of inflammatory cascade leads to 
endothelial dysfunction and increase in systemic capillary permeability. 
In kidney there is loss of barrier integrity and capillary leak in the 
glomerulus results in increased excretion of albumin in the urine. This 
study was done to evaluate the degree of microalbuminuria in sepsis in 
correlation with APACHE II score and to test whether the degree of 
microalbuminuria could predict the mortality in critically ill sepsis 
patients. 
Methodology: 
The present study was conducted on 50 patients admitted to Medical 
emergency/ Medical ICU in Madras Medical College and Rajiv Gandhi 
Government General Hospital,Chennai. Spot urine sample was collected 
within 6 hours and at 24 hours of admission to medical emergency/ICU 
ward. Sample tested for urine micro albumin by using 
immunoturbidometric method and for urine creatinine by jafee method. 
Urine albumin: creatinine ratio was calculated. (At 6 hours ACR-1 and at 
24 hours ACR-2).APACHE II scoring was done at 24 hours of admission. 
Patients was followed up during the course of hospital stay and the 
outcome of the patient (i.e. Death/Survival) is recorded. 
Results: 
The present study included 50 patients, among which 31 were males and 
19 were females. Mean age was 43.5 years. Mortality was 38%. Mortality 
was more among male patients than in female. APACHE II score ranges 
from 6 - 37, mean APACHE II among survivors were 16.35 with 
Standard Deviation of 6.78 and among non survivors were 25.47 with 
Standard Deviation of 6.93 with p value of <0.0001 for predicting 
mortality.Urine ACR 1 was 74.06±20.83 µgm/mg among survivors and 
164.53±46.61 µgm /mg among non survivors and ACR 2 was 
45.81±17.92µgm/mg among survivors and 157.84±36.96 µgm/mg among 
non survivors. Both were statistically significant with p value of 0.0001 
for predicting mortality. The degree of  microalbuminuria correlates with 
disease severity. 
Conclusion: 
Significant microalbuminuria is predictive of mortality which is 
equivalent to APACHE II score. Microalbuminuria is an inexpensive and 
rapid diagnostic tool. Serial measurements may help in the clinical 
assessment of critically ill patients at risk of worse prognosis, even in 
resource poor areas. 
 
KEYWORDS 
Sepsis; microalbuminuria; APACHE II score; urine albumin creatinine 
ratio. 
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INTRODUCTION 
 
 SEPSIS is defined as SIRS (systemic inflammatory response syndrome) that 
has aproven or suspected microbial etiology. Invasive bacterial infections are the 
prominent causes of death around the world, particularly among young children. 
Non-typhoidal salmonella species, Streptococcuspneumonia, Haemophilus 
influenza, and Escherichia coli were the most commonlyisolated bacteria. 
 Sepsis is marked by a severe host defense response that involves triggering 
ofpotent inflammatory cascades which release a plethora of pro-inflammatory 
moleculesinto the circulation. The endothelium becomes dysfunctional due to the 
sustainedonslaught of the inflammatory molecules and the simultaneous oxidative 
stress. An earlyevent is the loss of barrier integrity leading to systemic capillary 
leak. Increased capillarypermeability is an early feature of Systemic Inflammatory 
Response Syndrome (SIRS). 
 The glomerular manifestation of this enhanced capillary permeability is 
increasedexcretion of albumin in the urine. In various studies microalbuminuria 
has beencorrelated with rapid changes in vascular integrity.Early prediction of 
mortality among critically ill sepsis patients and earlyinstitution of intensive 
therapy is of paramount importance which has significantimplications on survival 
of the patient. 
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 Various ICU scoring systems to predict mortality are in current use like the 
APACHE II and SAPS II score. These scoring systems are cumbersome and are 
done at24 hours of admission during which precious time is lost in administering 
therapy.Microalbuminuria, defined as 30–300 mg/day of albumin excretion in the 
urine,occurs rapidly after an acute inflammatory insult such as sepsis and persists 
in patientswith complications. It is a common finding in critically ill patients, 
where it has shownpromise not only as a predictor of organ failure and vasopressor 
requirement but ofmortality. This study is an attempt to understand the usefulness 
of Urine Micro albumin andcreatinine ratio in predicting scoring the mortality of 
the patient and to compare it with validatedsystems such as APACHE II 
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Aims and Objectives of the study 
 
1)To study the correlation between the degree of micro albuminuria and severity of 
sepsis. 
2)To evaluate whether the degree of micro albuminuria could predict mortality in 
sepsis. 
3)To develop a simple, inexpensive and dynamic marker of critical illness. 
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REVIEW OF LITERATURE 
Definition 
Septicaemias: 
The term septicaemia implies active replication in the blood of bacteria associated 
with systemic manifestations. ‘Bacteraemia’ means the presence of bacteria in the 
blood which may be transient and without symptoms. 
Septic shock :septic shock is characterized by hypotension (systolic BP less than 
90 mmHg), hypoxia, increased serum lactic acid levels, high-anion-gap metabolic 
acidosis, and oliguria with a urine output of less than 30 ml/h. Multiple organ 
dysfunction which may also include disseminated intravascular coagulation leads 
to a mortality of up to 50 percent. 
 
Sepsis has very high morbidity and mortality, which leads to major healthcare 
burden in the world. Though there is far advancement in the therapeutic options, 
the mortality rate remains high due to the delay in the diagnosis because of lack of 
availability of reliable diagnostic methods. There is significant improvement in the 
outcome of the patients in early goal directed therapy in severe sepsis and septic 
shock. 
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Pathogenesis of sepsis syndrome 
• Advances in unravelling the genetic basis and pathophysiology for the host 
responses to sepsis have changed the current understanding of the syndrome, 
and several therapies have shown surprising efficacy.In sepsis the antigens 
from infectious agent stimulate monocytes and macrophages which leads to 
release of pro inflammatory cytokines.  
• This potent activation of inflammatory cascade leads to endothelial 
dysfunction and increase in systemic capillary permeability. The endothelial 
injury and capillary leak in the glomerulus results in increased excretion of 
albumin in the urine. 
 
• In several systemic diseases renal involvement is the well-recognised 
complication. Renal blood flow contributes the major portion of cardiac 
output. Exogenous and endogenous agents involved in the pathogenesis of 
disease process traverse the glomerular circulation results in glomerular 
injury. This leads to the presence of microalbumin in the urine which is very 
well observed in multiple organ dysfunction syndrome 
(MODS).Albuminuria is the manifestation of glomerular capillary leak in 
diffuse systemic manifestation. 
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• Microbial factors 
    
 
Bacterial load 
  
Endotoxin (Gram -ve), teichoic acid (Gram +ve) 
  
Activation of complement cascade 
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• Host factors 
    
 
Systemic inflammatory response syndrome (SIRS) 
  
Release of immune mediators (IL-1 and TNF - a) 
  
Endothelial damage 
  
Activation of coagulation cascade 
  
Myocardial function  
• Result 
    
 
Tissue perfusion , BP , sensorium  
  
Oliguria and azotaemia 
  
Adult respiratory distress syndrome (ARDS) 
  
Disseminated intravascular coagulation (DIC) 
  
Shock 
T-cell receptor or immunoglobulins. 
• The innate immune system is activated by  cell wall components and 
secreted proteins which are produced by the microorganisms . Gram 
negative cell walls contain bacterial endotoxin and lipopolysaccharide .Both 
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of them are important in the pathogenesis of sepsis.1,2,3.
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• There are two components in endotoxin .  Lipid A is a component of 
endotoxin which plays a major role in immunostimulation.3The humans are 
more susceptible to the immunostimulation of sepsis.  
 
Lipopolysacharide 
• LPB is the binding protein for lipopolysaccharide. After binding to LPB , it 
is transferred to CD 14 expressed by leukocytes.4,5 Bactericidal increasing 
protein  is produced by polymorphonuclear cells and it causes modulation of 
the activity of  LPS prevents LPS from binding to LPB. Binding of LPS to 
LPB results in induction of  signal transduction, resulting in toll-like 
receptors (TLRs)activation .6,7 Which is mediated by CD14. 
 
Toll like receptors 
• TLRs are present even in invertebrates and plants. It causes regulation of 
defense against the microorganisms. Ten TLRs have been discovered . 
• The ligand specificity of TLR is of  wide range like 
lipoproteins,peptidoglycan, lipopolysaccharide, and lipoteichoic acid from 
various pathogens .8 TLR4 is the lipopolysaccharide receptor, Gram + cell 
wall components are predominantly recognized by TLR2, while flagellin is 
recognized by TLR5  and  bacterial DNA is recognized by TLR9. The TLRs 
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are transmembrane proteins. Toll like receptors and interleukin (IL)-1 
receptor have similar cytoplasmic domain .9 
• The role of toll like receptors are studies in the mice having mutations in the 
gene of toll like reptors.11,12Mice with mutations in toll like receptor 4 gene 
did not have any response to lipopolysaccharide and were resistant to toxic 
shock but mice with mutations in toll like receptor 2 gene were susceptible.13 
• Sepsis itself has been demonstrated to up-regulate expression of TLR2 and 
TLR4 .14In experimental models, immunomodulators that decrease 
expression or activation of TLRs decrease lethality. It has therefore been 
proposed that the exaggerated proinflammatory response characteristic of 
the acute respiratory distress syndrome (ARDS), SIRS, and severe sepsis 
may be due to overexpression of TLRs or the consequent excess activation 
of NF-kappaB and other nuclear transcription factors.15 
• Other than TLRs several other pathway by which recognition of 
microorganism is possible by the cells have been discovered . They are 
1.Peptidoglycan-recognition proteins (PGRPs).16,17 Different PGRPs can 
distinguish between Gram-positive and Gram-negative bacteria.  
2.TREM-1 and MDL-1 cause activation of monocytes .18,19  
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• There is a severe activation of innate immune system following initial 
interaction with microorganism which causes coordination of cellular and 
humoral components of immunity. Monocytes and lymphocytes release 
proinflammatory molecules Interleukin-1,  Interleukin-6, and tumor necrosis 
factor-alpha, but in addition to it Interleukin-8,  Interleukin-12,  Interleukin-
15,and Interleukin-18.  
• In addition antiinflammatory mediators (IL-4, IL-10, IL-ra) are produced to 
balance the proinflammatory mediators in an attemptto eliminate the foreign 
antigen. Pro inflammatory and antiinflammatory pathways are tightly 
regulated. These pathways are closely connected to other  pathways involved 
in homeostasis.  
To name a few, 
•  Lipid mediators 
•  Neutrophil-endothelial cell activation 
• Coagulation/fibrinolytic system 
• Nitric oxide production 
• Oxidant/antioxidant pathway  
• Acute phase proteins 
• Hypothalamic-pituitary-adrenal axis 
• Cell apoptosis  
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• Heat-shock proteins 
• All these pathways are liked with the feedback loops in a very complexed 
manner. Severe sepsis and septic shock occurs due to dyregulated 
homeostatic mechanisms. 
• TNF-alpha is the first proinflammatory cytokine to be released in sepsis, 
followed by interleukin-1, interleukin-6, and interleukin-8.20,21 Tumor 
necrosis factor  and interleukin-1 aresynergistic as well as similar in 
action.22-26 Second messengers are generated after they bind  to the receptors 
. the second messengers are phospholipase A2 and C , G proteins,  oxygen 
free radicals  and adenylcyclase.  
• In addition, a number molecule production are induced such as, 
1. ELAM 
2. Tissue factor 
3. ICAM-1 
4. Cyclooxygenase 
5. Fibrinolytic proteins 
6. Plasminogen activator inhibitor-1 
7. Clotting proteins 
8. Plasminogen activator 
9. Phospholipase A2 (PLA2) 
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10. Nitric oxide synthetase 
• The antiinflammatory cytokinesare  interleukin-4, interleukin-10, 
interleukin-13, and transforming growth factor-beta2. Switching of  TH1 to 
TH2 activation is done by anti inflammatory cytokines. Interleukin-1 and 
TNF-alpha are suppressed by them. 
 
ANNEXIN -1 
• Annexin-1 (ANXA-1), previously named lipocortin-1, is a 37kd protein 
produced by mononuclear cells during the resolution phase of sepsis that has 
potent antiinflammatory properties and protects against LPS lethality.27,28 
• ANXA-1 inhibits PLA2, inducible nitric oxide synthetase (iNOS), and 
cyclooxygenase-2 (COX-2), while it increases interleukin-10 release by 
macrophages.29 ANXA-1 prevents neutrophil adhesion to activated 
endothelium and inhibits neutrophil migration.30,31 
• The antiinflammatory cytokines is to keeps the inflammation under control. 
Homeostasis is achieved by a balanced pro and antiinflammatory mediators. 
SIRS and MODS occurs when this homeostasis is affected.32Excessive anti-
inflammatory cytokines will cause anergy resulting in a state more prone for  
infection.33 
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TISSUE FACTOR 
• The extrinsic pathway of coagulation system is mainly involved in the 
pathogenesis of sepsis. Intrinsic pathway can also be activated in sepsis by 
the endotoxin .Tissue factor  is highly thrombogenic.  
• Tumor necrosis factor-alpha, interleukin 1, and plasminogen activating 
factor complement increased tissue factor expression. The main source of 
tissue factor in sepsis is the granulocytes and monocytes. 
• Antibodies against tissue factor has been studied in experiment models. 
They have demonstrated the suppression of coagulation cascade .Tissue 
factor pathway inhibitor (TFPI) ,Thrombomodulin pathway and ATIII 
suppress the tissue factor mechanism 
The Microcirculation in Sepsis 
• Using orthogonal polarization spectral imaging, De Backer et al.36,37have 
demonstrated that as compared to control, patients with sepsis have a 
marked reduction in the number of small capillaries that are perfused, and 
that the microvascular flow improves with time in survivors but not in 
nonsurvivors.  
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• Furthermore, these authors and others have demonstrated that the 
microcirculatory changes with sepsis are rapidly reversed with vasodilators 
(topical acetylcholine, dobutamine, and intravenous nitroglycerine).38,39 
• The role of vasodilator agents such as nitroglycerine and prostacyclin, which 
recruit   capillaries and improve microcapillary flow in the management of 
sepsis, requires further study.40-42 
•  In a LPS model, Iba et al.  demonstrated that recombinant human activated 
protein C (rhAPC) improved microcirculatory flow through the inhibition of 
leukocyte-endothelial interaction and suppression of proinflammatory 
cytokine production .43  
ORGAN INVOLVEMENT IN SEPSIS 
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Glucocorticoid in sepsis 
• Whether critically ill patients commonly have adrenal failure is difficult to 
dispute.44,45 What remains controversial at this time is the diagnosis of this 
disorder. Although a random total serum cortisol or a total cortisol following 
250 µg corticotropin is commonly used to diagnose adrenal insufficiency, 
this test has a number of limitations. 
• Cortisol binding globulin decreases during infection and the affinity of the 
hormone to bind is also decreased during acute illness ,resulting in an 
increase in the free biologically active fraction of the hormone.  
• Furthermore, due to alterations in GR number and/or function neither the 
total nor free cortisol reflects tissue glucocorticoid activity.  
• Nevertheless, despite these limitations, a random total cortisol of less than 
15 µg per dL or a level less than 20 µg per dL after 250µg corticotropin in a 
patient with severe sepsis is generally regarded as diagnostic of CIRCI . 
Diagnosis 
Laboratory studies that may be considered include the following: 
• Complete blood count (CBC) – Usually not helpful 
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• Platelets are elevated in inflammation reduced in DIC 
• WBCs are usually elevated but sometimes suppressed 
• Coagulation studies Elevated prothrombin time, APTT 
• D-dimer in DIC, decreased fibrinogen levels in DIC 
• Renal function tests Abnormal in hypoperfusion renal failure 
• Liver function tests Helpful in localizing sepsis; consider biliary sepsis, 
especially in elderly patients with no obvious localizing signs 
• Blood cultures :Three sets of cultures must be obtained in all patients before 
administration of antibiotics 
• Urine cultures Part of the diagnostic workup for sepsis 
• Bacterial cultures – Blood cultures at admission; culture of the catheter tip 
(for suspected central IV line sepsis); nasal cultures (potential marker of MRSA 
risk) 
• Stained buffy coat smears or Gram staining of peripheral blood 
• Urine studies (Gram stain, urinalysis, and urine culture) 
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• Procalcitonin levels 
Imaging modalities that may be helpful include the following: 
• Chest radiography (to rule out pneumonia and diagnose other causes of 
pulmonary infiltrates) 
• Abdominal ultrasonography (for suspected biliary tract obstruction) 
• Abdominal CT or MRI  
The following cardiac studies may be useful if acute myocardial infarction (MI) is 
likely: 
• Electrocardiography (ECG) 
• Cardiac enzyme levels 
Invasive diagnostic procedures that may be considered include the following: 
• Thoracentesis (in patients with substantial pleural effusion) 
• Paracentesis (in patients with gross ascites) 
• Swan-Ganz catheterization (for helping manage fluid status and assessing 
left ventricular dysfunction in MI; not for diagnosis of sepsis per se) 
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• Lumbar puncture  
• cerebrospinal fluid examination :Performed after cerebral computed 
tomography in suspected meningitis; antibiotics should not be withheld until after 
cerebrospinal fluid is obtained 
 
MORTALITY AMONG PATIENTS WITH SEPSIS  
Severity of Disease Mortality (%) 
Systemic inflammatory response syndrome  : 7 % 
Sepsis       :16% 
Severe sepsis      :20% 
Septic shock      :46% 
 
UNFAVOURABLE FACTORS IN SEPSIS 
Host Factors 
Hypothermia (temperature < 35.5°C) 
Leukopenia (WBC < 4000/mm3) 
Arterial blood pH < 7.33 
Shock 
Multiorgan dysfunction (renal failure, respiratory failure, cardiac failure) 
Age > 40 years 
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Medical comorbidities 
Controversial Risk Factors 
Serum cortisol level 
Factors Under Study Risk 
Genetic polymorphisms (in genes encoding TNF-α, IL-1, IL-6) 
MANAGEMENT OF SEPSIS 
MANAGEMENT PRINCIPLES 
TREATMENT 
1) Identification and elimination of the septic foci 
• Removal of infected catheters or venous access devices 
• Identification and drainage of abscess 
• Debridement of infected tissue 
2) Fluid resuscitation guided by vital signs (including central venous pressure) and 
urine output. 
3) Initiate vasoactive agents if needed. 
4) Place central venous catheter and arterial cannula if needed. 
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5) Obtain antimicrobial cultures 
6) Broad-spectrum antibiotics (based on the particular risk factors for infection) 
and assessment of the patient's immune state. 
7) Supportive care and management of other symptoms 
• Oxygen, to keep saturations greater than 90 mm Hg 
• Treatment of delirium ,nausea ,vomiting and pain . 
• Intravenous Insulin for hyperglycaemia 
• Activated protein C (drotrecogin alfa) 
• Initiate prophylactic measures for venous thromboembolism and
 gastrointestinal haemorrhage 
• Initiate lung protective ventilation strategies 
ANTIBIOTIC THERAPY 
• The important management is to identify the organism, eradicate the focus 
of infection, eliminate pathogens from the blood stream, and correct organ 
dysfunction. Prompt and aggressive treatment is often successful but once 
septic shock supervenes the mortality rises sharply. 
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• Organisms causing sepsis in the community differ from those causing sepsis 
in hospital (nosocomial infection)  
• Fungal infections are seen today in increasing numbers in patients who are 
immunosuppressed because of renal transplants, malignancy or AIDS. 
Neutropenic patients are a special group where infections with Pseudomonas 
aeruginosa, Staphylococcus epidermidis and fungi (candida, aspergillus) are 
common.  
• Community-acquired sepsis with skin rash constitutes a distinct group where 
one has to consider conditions like toxic shock syndrome (Staph. aureus) or 
meningococcal septicaemia.The choice of antibiotics depends on the 
organism suspected and on the results of cultures.  
• Intravenously administered bactericidal antibiotics are required, occasionally 
in synergistic combination. Drug pharmacokinetics are altered in critically ill 
patients, requiring diligent attention to dosage schedules 
 Infections Organisms Antibiotics 
1. Community-acquired 
urinary tract infections 
E. coli 
Klebsiella 
Sulphatrimethoprim 
Ampicillin 
Quinolones 
Aminoglycosides 
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2. Community-acquired 
respiratory infection 
S.pneumoniae 
H.influenza 
Legionella 
Ampicillin with 
clavulanic acid 
Erythromycin 
Sulphatrimethoprim 
3. Community-acquired 
infection with skin rash 
Staph.aureus 
Meningococcus 
Cloxacillin 
Ampicillin with clavulanic 
acid 
Chloramphenicol 
Ceftriaxone 
4. Nosocomial sepsis Pseudomonas  
aeruginosa 
Enterobacter 
Serratia 
E.coli 
Acinetobacter 
Ceftazidine 
Cefaperazone 
Aminoglycosides 
Imipenem 
Aztreonam 
Antipseudomonal penicillins 
5. Sepsis with neutropenia Pseudomonas 
aeruginosa 
Staphylococcus 
Fungi 
As above 
Vancomycin 
Amphotericin 
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Hemodynamic Support : 
Intravascular Volume Expansion 
COLLOIDS 
• Because of increase in capillary permeability the interstitial volume is 
increased . Interstitial fluid volume  will be increased by crystalloid 
solutions  so they should be avoided for resuscitation. Colloidal solutions 
have more advantage over crystalloids. 46-48 
• Albumin and hydroxyethyl starch (HES) solutions are the colloidal solutions 
most commonly used in patients with sepsis. HES has a number of 
theoretical advantages over albumin. These solutions remain largely 
intravascular, with maintenance of an osmotic gradient for up to 200 hours 
post infusion .49In comparison, in septic patients albumin redistributes into 
the interstitium, expanding the interstitial volume equal to the volume of 
infused albumin. 
•  In addition, HES solutions have antiinflammatory properties and inhibit 
endothelial activation and endothelial-associated coagulation, resulting in 
less tissue edema.50-56. 
• The use of albumin in critically ill patients has been controversial. A well-
publicized metaanalysis of the use of albumin in critically ill patients 
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published in the British Medical Journal suggested that albumin 
administration increased mortality .57 
• In a recent landmark study, the Australian and New Zealand Clinical Trials 
Group (ANZICS) compared the effect of fluid resuscitation with 4% 
albumin with that of saline on mortality in 6,997 heterogeneous ICU 
patients.58 
• This study provides evidence that albumin is not harmful in critically ill 
patients with a suggestion that this volume expander may be preferable to 
saline in patients with sepsis. 
• In the absence of strong evidence, it is recommended that a resuscitation 
algorithm that combines the use of a crystalloid and colloid HES. Limiting 
the volume of crystalloids in this manner may decrease tissue edema, 
improve tissue oxygenation, and reduce complications. Such an approach 
has been demonstrated to reduce complications in postoperative patients .59 
Vasoactive Agents  
• Vasopressor therapy should be started if the patient fails the fluid challenge. 
In case of life threatening situations vasopressor therapy is immediately 
started.  
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• In spite of fluid resuscitation patients remain hypotensive because of 
peripheral vasodilation. Septic patients are hypo responsive to vasopressors 
hence high dose is needed. 
• Multi organ failure occurs because of failure to increase the tissueperfusion. 
However the right choice of inotropic agents in patients with sepsis are yet 
to be determined . 
NOREPINEPHRINE 
• Norepinephrineis  the first-choice vasopressor agent in sepsis.60  
Norepinephrine increases MAP due to its vasoconstriction, with little  On 
comparing with dopamine heart rate and  stroke volume are less affected.  
• Norepinephrine increases tissue oxygenation and splanchnic 
perfusion.Dopamine was initially the vasopressor of choice in sepsis .the 
chronotropic effect is not desired . Tachycardia and tachyarrhythmias are 
the major disadvantages.  
 
DOPAMINE 
• Myocardial oxygen consumption is increased in dopamine therapy resulting 
in myocardial ischaemia. 
• GI mucosal ischaemia is caused by dopamine. 
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• Prolactin is needed in patients with sepsis which is decreased in patients 
with sepsis. 
• Patients who remain hypotensive, have poor urine output after adequate 
volume resuscitation (4 to 5 L of crystalloid or equivalent) and are receiving 
high doses of norepinephrine (greater than 0.3 to 0.5 µg per kg per minute) 
require noninvasive or invasive hemodynamic monitoring.  
• Hypotension/inadequate organ perfusion in this situation may be due to 
severe vasodilatation, inadequate volume resuscitation, and/or severe 
ventricular dysfunction; the distinction between these entities is difficult to 
make clinically, and, therefore, hemodynamic monitoring is required.  
• Most patients with sepsis have a hyperdynamic circulation with a high 
cardiac output. However, some patients with septic shock have severely 
depressed myocardial function. This may arise either due to preexistent 
heart disease or sepsis-induced ventricular  dysfunction. In this situation 
ventricular function and cardiac output are best assessed by bedside 
transthoracic echocardiography or pulmonary artery catheterization.  
 
VASSOPRESSIN 
• Patients with poor left ventricular contractility despite adequate fluid 
resuscitation should receive a trial of dobutamine. Low-dose vasopressin 
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(0.01 to 0.04 U per minute) may be considered .While increasing blood 
pressure, experimental and clinical studies have shown that vasopressin 
(without a catecholamine) decreases oxygen consumption.  
• In addition, in both clinical and experimental studies vasopressin has been 
demonstrated to cause vasoconstriction of the mesenteric artery and to 
compromise gut mucosal microcirculation. vasopressin should only be used 
in patients with refractory septic shock (norepinephrine greater than 0.5 to 
1.0 µg per kg per minute) . 
• Due to its effects on cardiac output and oxygen flux, vasopressin should be 
used in conjunction with a catecholamine (norepinephrine) . 
 
EPINEPHRINE 
• Serum lactate level is increased in patients treated with epinephrine.  This 
increase in serum lactate level does not occur with other vassopressors.The 
increased lactate production may be due to increased glycogenolysis or a 
maldistribution of blood flow. In addition, in a canine septic shock model, 
compared with concurrent controls, which received antibiotics and 
intravenous fluid, the addition of epinephrine adversely effected survival . 
• There are limited data on phenylephrine in sepsis. Phenylephrine lowers the 
cardiac output . 
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• Outcome improves if early dialysis is stared in patients who don’t improve 
with aggressive fluid management .Continuous Renal replacement therapy 
is preferred as it does not cause much of hemodynamic unstability. 
Treatment with Stress Doses of Hydrocortisone
 
 
• In patients with vasopressor-dependent septic shock there has been a great 
deal of interest regarding the assessment of adrenal function and the 
indications for steroid replacement therapy. Treatment of septic shock with 
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stress  doses of hydrocortisone has been demonstrated to improve the 
hemodynamic status, down-regulate the proinflammatory response, and 
improve mortality . 
• Annane et al. in a landmark study, randomized 299 patients with septic 
shock to receive either hydrocortisone (50 mg intravenous every 6 hours) or 
placebo for 7 days.61 Patients were stratified as responders (delta cortisol 
greater than 9 mg per dL) or nonresponders (delta cortisol less than 9 mg per 
dL) based on a 250-µg corticotrophin test.  
• In this study 77% of patients were nonresponders. Overall the 28-day 
mortality was 55% in the steroid-treated group and 61% in the placebo 
group; in the nonresponders who were treated with hydrocortisone the 
mortality was 53%, and this compared to 63% in the nonresponders treated 
with placebo.  
• By Kaplan-Meier analysis the 28-day probability of survival was 
significantly better in the steroid treated group compared to the placebo 
group (odds ratio of 0.71; 95% CI, 0.53 to 0.97; p = 0.03).  
• Based on these data, treatment with hydrocortisone should be considered in 
all patients with septic shock. The role of adrenal function testing and 
treatment with stress doses of hydrocortisone in other groups of critically ill 
ICU patients remains to be determined. 
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Anticoagulation in Sepsis 
• Coagulation cascade activation results in extensive thrombosis which results 
in the development of multi organ dysfunction syndrome. As the alteration 
in microcirculatory blood flow is postulated to play a major role in 
thepathophysiology of sepsis 
 
 
• Studies have tested antithrombotic drugs in sepsis treatment. There is no 
evidence that mortality in sepsis decreases with heparin. 
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• Blood coagulation and inflammation can be suppressed by anti-thrombin III. 
Minimal levels of anti-thrombin III is present in sepsis .there may be a role 
of anti-thrombin III in treatment of sepsis. 
• Protein C levels are decreasedin patients with sepsis .Protein C levels are 
low in survivors than non survivors . Bernard et al. , in a randomized 
multicenter, double-blind trial (PROWESS) studied the efficacy of 
drotrecogin alpha activated (APC) on 28-day all-cause mortality rate in 
patients with severe sepsis. 62  
• Patients were randomly assigned to receive a continuous infusion of APC at 
24 µg per kg per hour or placebo intravenously for 96 hours. Subjects were 
randomized within 24 hours of onset of sepsis-related organ failure, such 
that the maximum time window for receipt of the study drug was 48 hours. 
A total of 1,690 randomized patients were treated (840 in the placebo group 
and 850 in the APC group).  
• The mortality rate was 30.8% in the placebo group and 24.7% in the APC 
group. APC was associated with a 19.4% (95% CI, 6.6 to 30.5) relative risk 
reduction and 6.1% absolute reduction in the risk of death (P = 0.005). A 
post hoc analysis revealed that the benefit was observed among subjects who 
had APACHE II scores of 25 or more (a 13% absolute reduction), while the 
subjects with lower risk showed no benefit from APC. Other subgroups in 
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which APC was beneficial included patients older than 50 years of age, 
patients with more than one organ system dysfunction, and patients who had 
shock at the time of the infusion . 
•  In addition to inhibiting thrombosis and promoting fibrinolysis, APC 
inhibits leucocyte-endothelial interactions and suppresses inflammatory 
cytokine production, thereby attenuating the microcirculatory injury of 
sepsis . These properties of protein C may partly explain why APC appears 
beneficial in sepsis, yet other anticoagulants such as ATIII have failed to 
improve the outcome in patients with sepsis. 
Summary of Advances in Managing Sepsis Based on Randomized Controlled 
Clinical Trials 
• Recombinant human activated protein C improves survival for severe 
 sepsis.62 
• Hydrocortisone in septic shock improves immunologic and hemodynamic 
 effects, but not outcomes . 
• Early goal-directed therapy improves outcomes in sepsis and septic shock.  
• No difference in outcomes with routine changes or exchanges or no change 
 of long-term catheters.  
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• Most important treatment of nonneutropenic Gram-negative bacteremia is 
 appropriate antibiotics, not combination therapy.  
• 0.9% NaCl, 5% albumin (0.9% NaCl), Hespan (and not Hextend), and 
 especially hypertonic saline solutions contribute to hyperchloremic 
 metabolic acidosis and may decrease renal and splanchnic blood flow. 
 Tifacogin (recombiant tissue factor pathway inhibitor) in severe sepsis has 
 no effect on all cause mortality in those with increased international 
 normalized ratio. It does increase the risk of bleeding irrespective of 
 international normalized ratio .63 
• In OPTIMIST study treatment with tifacogin did not decrease the mortality 
in the patients with severe sepsis.63 
Blood component therapy 
• Blood component therapy is dangerous in sepsisbecause the infused 
fibrinogen serves as a substrate which will further worsen the hemostasis. 
Coagulation factors infused will be destroyed by the circulating plasmin. 
• Administration of FFP increased the mortality in meningococcal sepsis in a 
study of 336 patients.64 
• Patients having hemorrhage severe thrombocytopenia and abnormal 
coagulation profile should be treated with fresh frozen plasma and platelets. 
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Should probably be coadministered with APC. Fibrinogen concentrates are 
not to be used. Coagulation profile should be closely monitored in 
replacement therapy. 
MODS 
Definitions 
• Bone  and others originally classified many of these patients with severe 
acute illnesses as having sepsis or the sepsis syndrome.65,66 Efforts by these 
investigators to develop a consensus led to the terms SIRS and MODS. 
• MODS has been defined as the presence of altered organ function in an 
acutely ill patient such that homeostasis cannot be maintained without 
intervention.  
• Multi organ dysfunctionsyndrome  is not an all-or-none condition, but rather 
a continuum. This important concept is incorporated in new definition of 
sepsis. Additional definitions commonly used in conjunction with MODS 
include SIRS, the compensatory antiinflammatory response syndrome 
(CARS), and the mixed antagonists response syndrome (MARS) . 
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Epidemiology 
The frequency of multi organ dysfunction syndromeranges from 7% in patients 
suffering from  multiple trauma, to 11% in the Intensive care unit patients. More 
than 60 % of deaths in surgical ICU is due to multi organ dysfunction. 
Etiology 
• In a survey of 2,475 patients with MODS, Zimmerman et al. found that 
nonoperative diagnoses accounted for most (76%) patients with MODS in 
the ICU.67 These authors found that six primary reasons for ICU admission 
accounted for half of the nonoperative diagnoses including sepsis, 
pneumonia, congestive heart failure, cardiac arrest, and upper 
gastrointestinal bleeding. 
• Most of the patients with MODS have been diagnosed to have sepsis. 
Patients may develop multi organ dysfunction syndrome as a consequence of 
a primary infection orfollowing nosocomial infections . 
•  In more 30 % patientswith MODS, no focus of infection can be found on 
clinical examination or postmortem studies.  
• Other risk factors for the development of MODS include severity of disease 
(Acute Physiology and Chronic Health Evaluation [APACHE] II and III 
scores, resuscitation from circulatory shock, focus of devitalized tissue, 
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preexisting end-stage liver failure, age greater than 65 years, major 
operations, andsevere trauma.68,69 
Mechanisms of Multiorgan Dysfunction Syndrome 
The progression of organ dysfunction occurs in predictable manner. Respiratory 
failure is the first one to occur . It occurs in 72 hours.  
Liver failure    :5 to 7 days) 
G I bleeding     :10 to 15 days) 
Kidney failure     :11 to 17 days) 
The pathophysiology of multi organ dysfunction syndrome is not well known. 
Few postulated hypotheses are, 
Gut Hypothesis: 
• It is the most widely accepted theory. Splanchnic hypoperfusion can 
commonly occur following trauma, sepsis, shock. 
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• The diameter of central arteriole of villus is decreased by endotoxin which is 
dose dependent. 
• The gut requires more oxygen , hence they are more susceptible to hypoxia 
resulting in mucosal ischaemia. 
• The gut is highly susceptible to diminished tissue perfusion and oxygenation 
as it has a higher critical oxygen requirement than the whole body and other 
vital organs, and the mucosal counter-current microcirculation renders the 
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villi particularly vulnerable to ischemia . Mucosal ischemia leads to both 
structural changes and alterations in cellular function. 
• Reactive oxygen species are produced resulting in impairment of 
mitochondrial respiration . 
• Liver dysfunction may result in entry of the endotoxin into the circulation 
resulting in other organ injury. 
Endotoxin-Macrophage Hypothesis 
• In patients with MODS, infection with Gram-negative microorganisms is 
relatively common, so endotoxin has been proposed as a key mediator in this 
clinical syndrome. 
• In this hypothesis, after the initial event (i.e., sepsis, pancreatitis, trauma), 
MODS develops as a result of production and liberation of cytokines and 
other mediators by endotoxin-activated macrophages.  
• TNF-alpha, IL-1, IL-6, thromboxaneA2, prostacyclin, PAF, and nitric oxide 
(NO) are the proinflammatory mediators that have been involved in the 
development of MODS . 
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Tissue Hypoxia-Micro vascularHypothesis : 
• Micro and macro vascular changes results in hypoxia. Anemia , myocardial 
failure, hypoxemia, hypovolemiccauses decreased tissue oxygen delivery.  
• Organ failure results from extensive thrombosis due to altered homeostasis.  
The Two-Event Hypothesis 
• The two-event hypothesis concept says that first insult causes priming of the 
immune system. While the second injury results in severe response resulting 
in MODS 
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Integrated Hypothesis 
• In most patients with MODS, the development of this syndrome cannot be 
traced to a single cause. It is likely that MODS is the end result of 
dysregulated hemostasis involving most of the mechanism cited above. 
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Diagnostic Criteria and Scoring Systems 
There are about  thirty  different  scoring systems described to diagnose and 
quantify the severity of  multi organ dysfunction syndrome. 
Prediction of outcome cannot be done by SOFA score.Quantification of  
complications in critically ill patients can be done using SOFA 
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Current Management Strategies 
 
• The primary goal in the management of any critically ill patient must be to 
prevent the occurrence of a single organ failure and when possible specific  
corrective therapy of all identifiable risk factors for the development of 
MODS.  
• The importance of maintaining adequate tissue perfusion in high-risk 
patients has been increasingly recognized. The level of perioperative tissue 
oxygen debt has been related to the postoperative incidence of MODS and 
patient outcome . 
• It also has been shown that patients suffering from SIRS have an increase in 
oxygen consumption and an increase in resting energy expenditure, and 
more so, if the origin of SIRS is sepsis, suggesting that metabolic stress is 
greater in these patients. 
 
SCORES 
Sepsis is evaluated using various scoring systems like APACHE (Acute 
Physiological and Chronic Health Evaluation), SAPS II ,SOFA (Sequential Organ 
Function Assessment) etc.
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SAPS II  
Its name stands for "Simplified Acute Physiology Score", and is one of several 
ICU scoring systems.  
 
51 
 
This scoring system is : 
 Describe the morbidity and mortality of a patient when comparing the outcome 
with other patients. 
 Describe the morbidity and mortality of a group of patients when comparing the 
outcome with another group of patients. 
• It streamlines data collection and analysis without compromising diagnostic 
accuracy. The SAPS II is the most widely used version. It calculates a 
severity score using the worst values measured. Several of the variables (i.e., 
AIDS, metastatic cancer, hematological malignancy) are dichotomous, 
meaning that they are either present or absent.  
• The others are continuous variables that have been made categorical by 
assigning points to ranges of values. As an example, a systolic blood 
pressure ≥200 mmHg is worth 2 points, 100 to 199 mmHg is worth 0 points, 
70 to 99 mmHg is worth 5 points, and <70 mmHg is worth 13 points during 
the initial 24 hours in the ICU for 17 variables. 
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SAP III 
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APACHE SCORING:  
• APACHE is a reliable and useful means of classifying ICU patients. 
APACHE has also proved useful in evaluating outcome from intensive care 
and in comparing the success of different treatment . Original APACHE 
system was complex. 
• APACHE system incorporates a four-letter (A, B, C,and D) designation 
corresponding to a spectrum ranging from excellent health (A) to severe 
chronic organ system insufficiency (D 
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APACHE II CORRELATED WELL WITH SAP II THAN WITH MPM II 
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• The APACHE II system is the result of efforts to simplify. The weights for 
the nine remaining physiologic variables used in APACHE II are the same 
as in the original APACHE system. Unlike APACHE, however, 
measurement of all 12 physiologic values is mandatory when using 
APACHE II. This eliminates the problem of missing values and concerns 
about the assumption that an unmeasured variable was normal . 
• Although  arterial blood gas measurements may be inappropriate for some 
patients, exclusion of these values is not encouraged and should only be 
done when clinical judgment strongly suggests the results would be within 
normal limits.  
• Because severe chronic illness and age reflect decreased reserve they are 
added to APACHE II. Age is a very important risk factor associated with the 
mortality. It is found  that when controlled for acute physiologic 
derangement and age, three of the four chronic health classifications (B,C, 
and D) were associated with higher death rates. However, only the most 
severe chronic organ system insufficiency or immunocompromised state 
(class D) markedly influenced outcome.  
• Nonoperative and emergency surgery admissions have a substantially higher 
risk for death from their prior organ system insufficiency than elective 
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surgical admissions. (Surgery or postoperative patients are those admitted to 
the ICU directly from the operating or recovery room. All others are 
nonoperative.) This was probably because patients with the most severe 
chronic conditions are not considered to be candidates for elective surgery.  
• Therefore, nonoperative or emergency operative admissions with a severe 
chronic organ system dysfunction are given an additional five points, while 
similar elective surgical admissions are only given two points. The 
maximum possible score is  71. There is no patient who has crossed 55. 
• Description of the disease is combined with APACHE II score, especially 
for those diseases with a good overall prognosis (as indicated by a very 
negative coefficient, such as acute asthma or diabetic ketoacidosis) and those 
with a poor prognosis (corresponding to a large positive coefficient, such as 
septic shock) 
• Classification would be more appropriate if done at an early point in time, 
such as in the emergency room or at the time of ICU admission. This would 
make the severity classification more independent from treatment. 
• When  the  association between admission and worst-value APACHE II 
scores on a subset of GWUMC patients was tested, in 88% of the 
physiologic measurements the worst value over 24 h was the ICU admission 
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value. Also, 8 1 % of APS scores changed less than five points when using 
admission  values only.  
• However, although APACHE II scores based on admission values were 
close to those obtained using worst values over the initial 24 h, they were not 
identical. Therefore, many studies  are in the process of further comparing 
initial values and worst 24-h values. Until this is completed, investigators 
must still use the worst value over 24 h.  
• The ability to classify patient groups according to severity of illness will 
provide researchers with a new tool for improving the treatment of 
criticallyill patients.  
• APACHE II can be very useful in clinicaltrials or in nonrandomized or 
multi-institutional studies of therapeutic efficacy. By providing a measure of 
severity of disease, APACHE II scores will help investigators determine 
whether control and treatmentgroups are similar.  
• APACHE II predictions correlated well with the burns index. The use of the 
burn index has made it possible for investigators to demonstrate an overall 
improvement in the quality of burn care during the last decade. Similar 
comparisons would be possible for intensive care using APACHE II data 
collected over time. 
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•  Like the Glasgow coma score,APACHE II should also be able to help 
determine whether new therapeutic interventions really benefit severely ill 
patients.  
• In studies of specific disease groups, APACHE II scores can tell only less 
about the severity of disease. Additional indicators of severity, such as 
serum albumin and anergy testing for nutritional studies,or pulmonary 
mechanics for respiratory surveys can be used.  
• The importance of APACHE II is that it combines in one summary measure 
the risk factors of physiologic derangement, age, and poor chronic health 
status. This is an improvement over the comparison of mean values which 
do not take into account comorbidity, interaction of variables from different 
organ systems, or important physiologic threshold. 
• The original APACHE system demonstrates that the degree of physiologic 
derangement correlates closely with the need for admission and continued 
stay in an ICU for low-risk monitored patients.  
• Because it is less complex and still relatively independent of therapeutic 
decisions, the APACHE II system should be even more useful for such 
questions or for determining the relative benefit of an invasive procedure. 
For specific research questions, it is  suggested using only the 12 
physiologic. 
59 
 
 
APACHE II 
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PROTEINURIA:  
• Proteinuria designates the presence of elevated ( nonphysiological) levels of 
proteins in urine (>200 mg/24 hr).During proteinuria the urine contains 
mainly of filtered plasma proteins and tubular Tamm-Horsfall proteins.The 
later is normal compound of urine produced mainly locally in the thick 
ascending limb of loop of Henle.  
• Albumin is the main plasma protein, and an increased concentration of 
albumin in the urine is usually referred to as albuminuria. Even a small 
increase in urinary excretion of albumin (UAER), microalbuminuria (30 – 
300 mg/24 h),is an early feature of many renal disease but is also established 
marker of endothelial dysfunction or the general health of vascular system.  
• Micro albuminuria may also be a normal phenomenon, eg in strenuous 
physical exercise.it also seen in early diabetes, myocardial infarction. After 
trauma, knee and hip surgery microalbuminuria is significantly elevated. 
Low molecular weight proteinuria can occur in interstitial renal disease, such 
as in interstitial nephritis, lithium nephropathy, or unspecifically in Chronic 
kidney disease (CKD)(interstitial fibrosis). 
• Some rare renal syndromes can also present with tubular, low molecular 
weight proteinuria. These syndromes include for example Dent’s disease 
(CLC5-defect), Imerslund-Grasbeck  syndrome (cubilin deficiency) , Lowe 
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syndrome and cystinosis, all due to deficient proximal tubular reabsorption 
(PTR). 
• Glomerular filtration of albumin is followed by tubular reabsorption (up to 
98%) and thus albuminuria reflects the net result of these two processes 
together. Glomerular proteinuria is caused by a defect in the GFB. 
Characteristic for this type of proteinuria is that large plasma proteins that 
normally not are filtered, or only filtered to a limited extent, appear in the 
urine. 
• Tubular proteinuria involves an impaired reabsorption of proteins by the 
tubular system. Smaller proteins that are freely filtered in the glomerulus and 
normally completely reabsorbed, can reach the urine when there is damage 
to the tubular system.  
• Even for a normally functioning proximal tubule, tubular proteinuria can 
occur. Thus, when increasing amounts of proteins are filtered across the 
glomerular barrier they start to interface with the normal tubular 
reabsorption of low molecular weight proteins, competing for the binding 
sites on the receptors in the tubular system. This is generally called 
“overload proteinuria”.  
• Overproduction of various proteins, such as light chains in plasma in 
multiple myeloma, usually also produces a kind of overload proteinuria, 
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“Overproduction proteinuria” (Bence Jones proteinuria). Low molecular 
weight proteins are then, due to their increased plasma concentrations, 
filtered in higher amounts and when the tubular maximum is exceeded, thy 
appear in the urine. 
Endothelial cells: 
• Endothelial cells are coated, on the plasma side, by a negatively charged 
glycocalyx consisting of glycosaminoglycans and proteoglycans. Enzymatic 
degradation of glycocalyx of the glomerular capillaries results in increased 
permeability of the glomerulus to the albumin resulting in microalbumiuria. 
• Glomerular capillaries are the vascular bed which are more susceptible to 
vascular injury.  This is caused by activation of coagulation cascade by the 
endotoxin , release of tissue factor, fibrin deposition in the capillaries, and 
low fibrinolytic activity .  
• In addition, activated neutrophils and a range of cytokines, such as IL-lb, 
TNF and platelet activating factor, are also implicated in the pathogenesis of 
endothelial injury. Acute renal failure occurs due to occurrence of micro 
thrombosis in the capillaries . It is well supported by human as well as 
experimental studies. 
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ENDOTHELIAL CELL DYSFUNCTION 
 
 
MICROALBUMIURIA 
• Because of high permeability of albumin in the glomerulus ,there is leakage 
of small amount into the urine resulting in microalbuminuria. The term 
microalbuminuria has been replace by KIDIGO as moderately increased 
albuminuria..  
• The tubular reabsorptive  mechanism for albumin from the ultra-filtrate is 
exceeded beyond its threshold capacity, leading to increased excretion   of 
albumin in the urine. The degree of albuminuria is dependent on the 
intensity of the inflammatory responses, and therefore micro albuminuria 
reflects disease severity found to be prevalent in a broad spectrum of 
critically ill patients. 
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Pathophysiological changes in the kidney associated with albuminuria 
• There are few changes in the microvasculature of kidney. Several hypothesis 
have been suggested . They are, 
Hypothesis 1 
• Glomerular permeability is changed 
• Proximal tubular reabsorption is decreased. 
 
Hypothesis 2 
• It is due to generalised endothelial dysfunction. 
• Glomerular barrier is affected. 
• Tubular metabolism and reabsorption are impaired. 
• Reduction in basement membrane negative charge due to loss of 
proteoglycan. 
• Pore size is increased. 
• Heparansulfate plays a major role . It not only maintains the electro 
negativity but also maintains the pore size thus preventing  micro 
albuminuria. 
• Other mechanism includes podocyte dysfunction affecting the filtration 
barrier. 
65 
 
• Mesangial cell growth is inhibited by heparin sulphate . In DM there is 
mesangial expansion and reduced filtration suface area. 
• Increase in filtered albumin cause renal dysfunction .Increased load on the 
tubules to absorb albumin may result in interstitial inflammatory injury and 
result in renal dysfunction. 
• Micro albuminuria was the reason for increased incidence of mortality in 
critically ill patients. It is probably the result of widespread endothelial 
dysfunction arising from the effects of cytokines, and other inflammatory 
mediators, released during the intense inflammatory responses that are 
associated with critical illness.  
• The effects of disruption of the integrity of the endothelial barrier is 
manifested as altered glomerular endothelial permeability in the kidneys, 
allowing increased amounts of albumin to escape into the glomerular ultra-
filtrate.  
• The tubularreabsorptive  mechanism for albumin from the ultra-filtrate is 
exceeded beyond its threshold capacity, leading to increased excretion   of 
albumin in the urine.  
• The degree of albuminuria is dependent on the intensity of the inflammatory 
responses, and therefore micro albuminuria reflects disease severity found to 
be prevalent in a broad spectrum of critically ill patients. 
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• The final common pathway for micro albuminuria is increased endothelial 
permeability which occurs due to various  mediators, like neutrophil 
,macrophage, complement activation,  and endothelial stimulation resulting 
in inflammatory injury. 
 
 
Sample 
Lower level 
 
 
Upper levels Unit 
24h  
 
30 300 mg/24h  
Short-time  
 
20 200 µg/min  
Spot  
 
30 300 mg/L  
Spot urine ACR  
3.5 35 mg/mmol  
30 300 µg/min  
 
• The glomerular manifestation of sepsis is microalbuminuria. 
Microalbuminuria is a marker of endothelial dysfunction. The traditional 
method  of  24-h urine samples collection for detection of microalbumiuria  
is cumbersome and it takes a lot of time . It may result in collection errors 
and poor compliance.  
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• Immunonephelometricmethod ,ELISA , Radial immunodifussion, 
immunoturbidmetric  method and  radio immno assay  have been used for 
the albumin measurement in urine.  
 
• The presence of microalbuminuria occurs very early in the onset of 
inflammatory process in sepsis and it persists in complications of sepsis. 
urinemicroalbumin occurs within the first first six hours following ICU 
admission.  
• The microvascular effects of systemic inflammation can be monitored by 
serial measurement of microalbumin in urine.  
• Microalbuminuria is better indicator than  Acute Physiological and Chronic 
Health Evaluation II (APACHE II) score and Sequential Organ Function 
Assessment score (SOFA score) in predicting vasopressor requirement and 
mortality. 
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• Occurrence of microalbuminuria correlated with the other biomarkers of 
sepsis like procalcitonin (PCT), CRP and cell adhesion molecules. Cell 
adhesion molecules are involved in the pathogenesis of endothelial injury 
resulting in MODS. 
 
• Intercellular adhesion molecule-1, Endothelial leukocyte adhesion 
molecules and vascular cell adhesion molecule-1  are  the cell adhesion 
molecules raised during systemic inflammatory response syndrome. Cell 
adhesion molecules are elevated in patient with sepsis when compared 
with patients who suffered trauma. 
 
• C- reactive protein does not correlate with the severity the disease and it 
is not specific and has a very slow induction time.  
 
• Procalcitonin  has a lot of advantages over C- reactive protein. It has 
more specificity and sensitivity compared to C- reactive protein. But the 
induction time of procalcitonin is slower than microalbuminuria. 
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• Endothelial dysfunction may occur in many aseptic conditions which are 
not due to sepsis. It is not known whether there is difference in the degree 
of microalbuminuria in sepsis when compared to non infectious insults 
like burns , pancreatitis, trauma, myocardial infarctionetc. 
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• 
 
Early morning ACR correlates better than spot ACR with the 24 hr 
ACR. 
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• Thorevska N et al conducted a study to ascertain the significance of urine 
microalbumin in evaluating the prevalence, predictors and prognosis of 
critically ill medical patients. 
•  In 104 critically ill patients, microalbuminuria or proteinuria was present 
in 60% of patients and the albumin creatinine ratio of more than 100 
mg/gm was observed in 43.3%. The median APACHE II score was 
observed as 20.5% and the median SOFA score was 5.0.Tere is 26.9% 
overall mortality rate in this study.  
• In critically patients there is high prevalence of microalbuminuria and the 
risk of mortality in  2.7 times higher in patients with ACR >100 mg/gm 
compared to others.69% patients had microalbuminuria or proteinuria on 
admission and 43.3% had ACR >100mg/gm.Median APACHE II and 
SOFA score was 20.5 and 5.0.Overall mortality rate was 26.9%. 
• He concluded that the prevalence of microalbuminuria is high in 
critically ill patients and ACR is more than 100 mg/gm were 2.7 times 
increased risk of mortality when compared to patients with ACR<100 
mg/gm.70 
• A study done by Gopal S et al concludes that microalbuminuria is an 
independent predictor of severity of illness and mortality in ICU 
patients.71 
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• A study done by Abid et al to assess the microalbuminuria as a predictor 
of the development of multiple organ dysfunction (MODS) and acute 
respiratory failure (ARF) in ICU patients. 
•  Patients in this study were divided into 2 groups. Patients with increased 
level of microalbumin in 48 hours from 5.2 mg/dl  ± 2.0mg/dl to 19mg/dl  
± 3.0mg/dl are included in group 1. Patients with decreased level of 
microalbumin in 48 hours from 16.4mg/dl  ± 4.8mg/dl to 7.8mg/dl ± 
3.0mg/dl are included in group 2.Group 1 had higher mortality rate 
(43%) when compared to other group (p<0.05).The higher SOFA score 
and APACHE II score were observed in group 1(43%) when compared to 
other group. The increasing value of urine microalbumin has 100% 
negative predictive value for the development of ARF and 96% for 
MODS.72 
• Todi et al conducted a study in critically ill patients to evaluate the 
degree of urine microalbumin to predict the diagnosis of sepsis. 
Concluded that absence of significant microalbuminuria is unlikely to be 
associated with sepsis without significant microalbuminuria.73 
• Study conducted by Basu et al to find out the correlation of degree of  
urine microalbumin in patients with sepsis and non-sepsis and to predict 
the mortality  in critically ill ICU patients. Patients in this study were 
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divided into 2 groups. Patients with sepsis were included in group 1 and 
those without sepsis  were included in group 2.  
• The median ACR -1 (ACR on admission) was higher (206mg/gm,IQR 
129.7 – 506.1) in group 1, compared to the other group (76.4mg/gm,IQR 
29 – 167.1), p-value =0.0016.The discrimination between sepsis and non 
sepsis may be made at a cut-off value of 124mg/dl with 80% 
sensitivity,64.1% specificity,30% positive predictive value and 87.3% 
negative predictive value.  
• The median ACR II (at 24 hours of admission) (154mg/gm,IQR 114 – 
395.3mg/gm) was higher in non-survivor than survivor (50.8mg/gm,IQR 
21.6 – 144.7mg/gm). The cut-off value of 99.6mg/gm could predict 
mortality with sensitivity – 68% negative predictive value – 97%,positive 
predictive value of 30%. 
• It is unlikely that patient without significant microalbuminuria has 
sepsis.Abscence of elevated microalbuminuria at 24 hours of admission 
has high predictive value for survival, which is comparable to APACHE 
II score.74 
• A study conducted by Makris et al evaluated the  significance of micro 
albuminuria as an early marker of endothelial dysfunction that 
accompanies Systemic Inflammatory Response Syndrome. He concluded 
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that there is a significant correlation between microalbuminuria and 
organ dysfunction. 
• A study undertaken by Berton G et al(2000)found that Albumin 
Excretion Ratio (AER) increases during Acute  MI and that it correlates 
with the prognosis.75 
• Similar study conducted on patients with sub arachnoid haemorrhage by 
Terao Y et al found microalbuminuria in the sub arachnoid haemorrhage  
patients was associated with poor prognosis.76 
• A study done by gosling et al(2003)found that mortality was associated 
with microalbuminuria. P value was 0.0002 when compared between the 
survivors and non survivors. P value was 0.0021 for the association 
between hospital stay and microalbumiuria. P value was significant for 
the association between serum creatinine, CRP and bilirubin.77 
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METHODOLOGY 
 
STUDY: STUDY OF MICROALBUMINURIA IN SEPSIS WITH 
REFERENCE TO APACHE II SCORE 
 
Source of data : 
 The study was conducted on patients admitted to medical ICU/Medical 
emergency ward, Institute of Internal Medicine, Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai after getting ethical committee 
approval. 
Method of data collection: 
 a) Studydesign:Prospective, on-interventional study in a tertiary care   
   hospital. 
 b) Sample size: 50  
 c)Samplemethod:Simple random sampling. 
 d)Duration of study: 6 months. 
 e)Method of collection of specimens and processing: 
• Spot urine sample was collected within 6 hours and at 24 hours of admission 
to medical emergency/ICU ward. Sample tested for urine micro albumin by 
using immunoturbidometric method and for urine creatinine by jafee 
method. Urinealbumin: creatinine ratio was calculated. (At 6 hours ACR-1 
and at 24 hours ACR-2). 
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• APACHE II scoring was done at 24 hours of admission. 
Patientswasfollowed up during the course of hospital stay and the outcome 
of the patient (i.e. Death/Survival) is recorded. 
f) Inclusion criteria: 
• Patients admitted to medical emergency ward/medical ICU    in Institute 
of Internal Medicine, Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai, with features of SIRS (systemic 
inflammatory response syndrome) and suspected infection . 
Systemic inflammatory response syndrome(SIRS): 
Presence of two or more of the following: 
• Fever(oral temperature more than 380C) or hypothermia(less than 
360C). 
• Tachycardia( heart rate more than 90 beats per min). 
• Tachypnea(more than 24 beats per min). 
• Leukocytosis(more than 12,000/µL), leukopenia(less than 4.000/µL) 
or presence of more than 10 percent bands. 
 
g)Exclusion criteria: 
o Diabetes Mellitus 
o Systemic hypertension 
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o Patients with preexisting chronic kidney disease/Patients with 
proteinuria due to renal/post renal causes 
o Patients with preexisting urinary tract infection 
o Patients receiving nephrotoxic drugs 
o Patients with urologic trauma resulting in frank hematuria or urinary 
tract infection 
o Anuria 
o Pregnancy/menstruation 
o Patients less than 16 years 
h) Investigations: 
 White blood count(total count & differential count) 
 hemoglobin 
 platelet count 
 Blood urea 
 serum creatinine 
 Serum electrolytes 
 Random blood sugar 
 Liver function test 
 Fasting blood sugar,  
 post prandial blood sugar 
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 Urine culture sensitivity 
 Blood culture sensitivity 
 Sputum culture sensitivity(if needed) 
 Arterial blood gas analysis 
 Chest X ray 
 ECG/USG KUB/Abdomen(if needed) 
 CSF analysis(in suspected meningitis) 
 
 
Data was collected using a pre tested proforma meeting the objectives of the 
study. Detailed history, physical examination and necessary investigation 
wasundertaken. The purpose of the study was explained to the patient and 
informed consent obtained. Patient was followed up during the course of the 
hospital stay and the outcome of the patient (i.e.death/survival) is recorded. 
 
Data Analysis and interpretation: 
 Data was entered into Microsoft excel and analysis were done using the 
statistical Package  for Social Sciences (SPSS) for windows software (version 
18.0;SPSS Inc, Chicago).The chi-square test and fisher’s exact test was used to 
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show the associations between predictor and outcome variables. The level of 
significance was set at 0.05. 
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OBSERVATION AND RESULTS 
Distribution of patients according to age group 
AGE IN 
YEARS 
DEATH SURVIVED TOTAL 
No. % No. % No. % 
< 20 1 2 4 8 5 10 
21-40 10 20 6 12 16 32 
41-60 7 14 18 36 25 50 
> 60 1 2 3 6 4 8 
TOTAL 19 38 31 62 50 100 
MEAN 43.5 ±15.8 
RANGE 16-85 
In this study the lowest age in this group of patients was 16 Years and the 
highest age in this group was 85 Years. The mean age of the study group was 43.5 
with the SD of 15.8.  
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Distribution of patients according to age group 
sex 
DEATH SURVIVED TOTAL 
No. % No. % No. % 
MALE 14 28 17 34 31 62 
FEMALE 5 10 14 28 19 38 
TOTAL 19 38 31 62 50 100 
In this study out of 50 patients, 19 were female(38%) as compared to 31 
male (62%).Among the 19 Non Survivors 5 were female (26.21 %) and 14 were 
male (73.68%). Among the 31 survivors 14 were female. 
 
 
0 
20
40
% of Patients 
MALE FEMALE
SEX
SEX DISTRIBUTION
SURVIVED%
DEATH %
82 
 
Distribution of patients according to no of SIRS criteria 
In this study out of 50 patients 27(54%) patients had all the four criteria for SIRS 
and 19 patients (38%) had three criteria of SIRS and 4 patients (8%) had only two 
criteria.The mortality rate for the patients who were having four criteria of SIRS 
was 33.33%. and who were having three criteria of SIRS were 42.1%. 
 
NO OF 
SIRS 
CRITERIA  
DEATH SURVIVED TOTAL 
No. % No. % No. % 
2 2 4 2 4 4 8 
3 8 16 11 22 19 38 
4 9 18 18 36 27 54 
TOTAL 19 38 31 62 50 100 
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Distribution of patients according to outcome 
 
 
 
 In this study out of 50 patients 19 patients(38%) were  not survived and 31 
patients(62%) servived. 
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Distribution of patients according to APACHE II score 
APACHE 
II 
DEATH SURVIVED TOTAL 
  No. % No. % No. % 
< 18.5 4 8 19 38 23 46 
>18.5 15 30 12 24 27 54 
TOTAL 19 38 12 62 31 62 
MEAN 25.47±6.93 16.35±6.78 19.82±8.11 
RANGE 6 – 37 
P Value <0.0001 
 
 In this study out of 50 patients APACHE II score ranged from 6 to 37 with a 
mean value of 19.82(SD±8.11). Out of 36 patients who had APACHE II score of 
more than 18.5, 15 patients died (55.55%), when compared to patients who had 
APACHE II score of less than 18.5, four patients died (17.39%) 
 The mean APACHE II score among t he survivors was 16.35 with Standard 
Deviation of 6.78, when compared to the mean value of non survivors was 25.47 
with Standard Deviation of 6.93 .As the P value was <0.0001, hence it was 
statistically significant. 
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Distribution of patients according to urine ACR 1 
ACR 1 
DEATH SURVIVED TOTAL 
No. % No. % No. % 
< 109.5 3 6 31 62 34 68 
>109.5 16 32 0 0 16 32 
TOTAL 19 38 31 62 50 100 
Mean 164.53±46.61 74.06±20.83 108.44 ± 55.05 
Range 33 – 245 
P Value < 0.001 
 
In this study out of 50 patients Urine Micro Albumin Creatinine Ratio done on 
admission ranged 33 to 245 microgram/mg. 
 
Out of 16 patients (32%) who had ACR 1 value more than 109.5, all the 16 
patients died.Out of 34 patients (68%) who had ACR 1 value less than 109.5, three 
patients died (8.82%).There is statistically significant P value of < 0.0001. 
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Distribution of patients according to urine ACR 2 
ACR 2 
DEATH SURVIVED TOTAL 
No. % No. % No. % 
< 118.5 3 6 31 62 34 68 
>118.5 16 32 0 0 16 32 
TOTAL 19 38 31 62 50 100 
Mean 157.84±36.96 45.81±17.92 88.38±60.96 
Range 15 – 221 
P Value < 0.001 
In this study out of 50 patients Urine Micro Albumin Creatinine Ratio done 
at 24 hours of admission ranged 15 to 221microgram/mg. Out of 16 patients (32%) 
who had ACR 2 value more than 118.5, all the 16 patients died.Out of 34 patients 
(68%) who had ACR 2 value less than 118.5, three patients died (8.82%).There is 
statistically significant P value 
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Comparison of urine ACR 1 AND urine ACR 2 amoung surviour and 
non-surviour 
 
 
Urine ACR 1 WAS 74.06 µgm/mg amoung surviours and 164µg/mg amoung non 
surviours and ACR 2 was 45.81 µg/mg amoung surviouras and 157 µg/mgamoung 
non surviours.both were statistically significant with p value <0.0001. 
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Co-relation between Micro-Albuminuria and APACHE II score 
 
 Mean Standard Deviation 
APACHE II SCORE 19.82 8.113 
URINE ACR 1 88.38 60.960 
URINE ACR 2 108.44 55.055 
 
Co-relation Co-relation Co-
efficient 
P value 
Urine ACR 1 and 
APACHE II score 
0.809 <0.0001 
Urine ACR 2 and 
APACHE II score 
0.726 <0.0001 
Urine ACR 1 and Urine 
ACR 2 
0.912 <0.0001 
 
There is good co-relation between Urine ACR 1 and APACHE II score. The P 
value is <0.0001, which is statistically significant. 
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Comparison of  Area under curve for APACHE II Score,ACR1 and ACR 2 in 
predicting mortality 
 
Test Result Variable Area Under Curve 
APACHE II score 0.701 
 URINE ACR 1  0.905 
URINE ACR 2 0.921 
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 The area under curve was Larger for Urine ACR 2 (92%), when compared to 
APACHE II score (70%). Urine ACR 1 (AUC 90.5%) also has comparable value 
with ACR 1 value. This implies, ACR 2 and ACR 1 had better correlation with the 
mortality of the patients when compared to APACHE II score. 
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DISCUSSION 
 
1) AGE 
Patients were distributed from age 15 to 85 years with age >60 years constituting 
8%.Mean age of the study population was 43.5 years (SD 15.8). 
A study conducted by S Todi et al (2010)  showed mean age of 58.17 years (SD 
18.66) and a study done by Angus DC et al showed mean age of 57.0[8] .Patients 
with age > 60 years constituted 34.8% of the study population.73 
 
2) SEX 
In the present study 19 patients (38%) were female and 31 patients were male 
(62%).In a study conducted by S Todi et al in India which studied epidemiology of 
sepsis in which male patients constituting 57.71%.73 study done by Angus DC et al 
78 showed male patients constituted 51.9% and the study done by S Sreedharan et al  
showed male patients constituted 60.5%. This study shows that sepsis is more 
common among males compared to females.79 
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Comparision of sex distribution of patients with other studies. 
Study Angus DC et 
al 
S todi et al Study S 
sreedharan et al 
Present 
study 
% male 51.9% 57.71% 60.5% 57.81% 
%female 48.1% 42.29% 39.5% 38% 
 
3) CO-MORBID ILLNESS 
In this study done out of 50 patients, 4 patients (8%) had COPD and patients (5%) 
had systemic hypertension, 4 patients had (8%) had Decompensated Chronic Liver 
Disease (DCLD) and 4 patients (8%) were Immunocompromised (HIV). A study 
done by Angus DC et al78 showed that COPD was the most common underlying 
co-morbidity which was present in 12.3% of the patients. 
 
4) SIRS CRITERIA 
In the present study 27 patients (54%) had all the 4 criteria for SIRS, 19 patients 
(38%) had 3 criteria and 4 patients (8%) had 2 criteria. 
 
5) ORGAN DYSFUNCTION 
Cardiovascular system: 33 Patients (66 %) had cardiovascular system 
dysfunction in the form of MAP < 70 mmHg, mean ACR1 and ACR2 were 116.45 
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μg/mg and 101.09 μg/mg among patients with cardiovascular dysfunction and 
92.88 μg/mg and 63.7 μg/mg amoung patients with no cardiovascular dysfunction. 
P value was statistically significant. 
 
Renal system: 19 patients(38%) had renal dysfunction in the form of urine output 
<0.5L/24 hr. Median ACR1 and ACR2 were 102 μg/mg and 84μg/mg among 
patients with renal dysfunction and 88 μg/mg and 53 μg/mg among patients with 
no renal dysfunction.P value was statistically significant. 
 
Haemotologic system: 7 patients (14 %) had haematologic dysfunction in the 
form of platelet count <80000/cumm. 
 
6) MORTALITY 
Mortality percentage in this study was 38%.This is consistent with various studies 
including study done by Rangel-Frausto MS et al 81which showed mortality 
ranging from 20-35% and study conducted by Greg S et al 2006 which showed 
case fatality increased linearly with age and age was an independent predictor of 
mortality.82 
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A study done by Angus DC et al showed that women had less age specific 
incidence and mortality rates compared to men. In this study out of 50 patients, 
among the 19 Non Survivors 5 were female(26.21 %) and 14 were male 
(73.68%).In this study mortaliy rate is higher in males than females. Among the 19 
patients who died 7 (36.84%) had an infectious source in the lung. Other causes 
included localized infection in the form of cellulitis or abscess or an abdominal 
source of infection. Urinary tract infections were excluded from the study as it was 
an exclusion criteria of the study. 
 
A study done by Angus DC et al 73 showed that 44% of the cause of 
mortality had a respiratory source of infection, 17.3 % had bacteremia from an 
unidentified source and 8.6 % had an abdominal source and 6.6 % had local wound 
as a source of infection. 
 
Similar study done by dolin et al83 showed that most common primary 
sources of infection resulting in sepsis are the lungs, the abdomen, and the urinary 
tract.Of the 19 patients who died 4 patients(8%) were immunocompromised. 
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Comparison of mortality percentage with other studies  
Study Ron Daniel 
et al84 
Rangel 
frausto et 
al81 
Russel et al Present 
study 
% male 35% 20 - 35% 20 – 35% 38% 
 
7) APACHE II SCORE 
In this study out of 50 patients APACHE II score ranged from 6 to 37 with a mean 
value of 19.82(SD±8.11). Out of 36 patients who had APACHE II score of more 
than 18.5, 15 patients died (55.55%), when compared to patients who had 
APACHE II score of less than 18.5, four patients died (17.39%) 
 
 The mean APACHE II score among the survivors was 16.35 with Standard 
Deviation of 6.78, when compared to the mean value of non survivors was 25.47 
with Standard Deviation of 6.93 .As the P value was <0.0001, hence it was 
statistically significant. 
 
8) URINE ACR 1(Albumin Creatinine Ratio): 
Urine for ACR (Urine Albumin Creatinine Ratio) collected on admission 
(Urine ACR1) and within 24 hour of admission (Urine ACR2).In this study out of 
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50 patients Urine Micro Albumin Creatinine Ratio done on admission ranged 33 to 
245 microgram/mg with mean value of 108.44 ± 55.05.Urine ACR1 differed 
significantly among survivors and non survivors. Patients who survived had mean 
ACR1 of 74.06 ± 20.83μg/mg and patients who died had mean ACR1 of 164.53 ± 
46.61μg/mg. 
ACR 1 Gosling et al 77  S Basu et al 74 Present study 
Surviour 70.4 108 84 
Non 
surviour 
168.6 156.6 158 
P value 0.0002 0.0004 0.0001 
 
 Out of 16 patients (32%) who had ACR value more than 109.5, all the 16 
patients died.Out of 34 patients (68%) who had ACR value less than 109.5, three 
patients died (8.82%).There is statistically significant P value of < 0.0001 for 
survivor and non survivor. 
9) URINE ACR 2 (Albumin Creatinine Ratio): 
 
In this study out of 50 patients Urine Micro Albumin Creatinine Ratio done 
on admission ranged 15 to 221 microgram/mg with mean value of  88.38 ± 60.96. 
Out of 16 patients (32%) who had ACR 2 value more than 118.5, all the 16 
patientsdied.Out of 34 patients (68%) who had ACR value less than 118.5, three 
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patients died (8.82%).Urine ACR 2 differed significantly among survivors and non 
survivors. Patients who survived had mean ACR2 of 45.81±17.92μg/mg and 
patients who died had mean ACR2 of 157.84±36.96μg/mg.There is statistically 
significant P value of < 0.0001 for survivor and non survivor.A study done by 
gosling et al showed that Urine ACR at 24 hours was 36.96 μg/mg among 
survivors and 156.64μg/mg among non- survivors with significant p value of 
0.0002(Mann Whitney test). 
 
Comparison of median Urine ACR2 with other studies ACR2: 
ACR 2 Gosling et al 23] S Basu et al[31]  Present study 
Surviour 36.96 50.8 46 
Non surviour 156.64 154 155 
P value 0.0002 0.0004 0.0001 
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SUMMARY 
 
Sepsis has very high morbidity and mortality, which leads to major healthcare 
burden in the world.Though there is far advancement in the therapeutic options, the 
mortality rate remains high due to the delay in the diagnosis because of lack of 
availability of reliable diagnostic methods. There is significant improvement in the 
outcome of the patients in early goal directed therapy in severe sepsis and septic 
shock.Potent activation of inflammatory cascade in sepsis leads to endothelial 
dysfunction and increase in systemic capillary permeablity.the endothelial injury 
and capillary leak in the glomerulus results in increased excreation of albumin in 
the urine. Microalbuminuria is defined as excretion of 30 – 300 mg of albumin per 
day in the urine. The presence of microalbuminuria occurs very early in the onset 
of inflammatory process. The microvascular effects of systemic inflammation can 
be monitored by serial measurement of microalbumin in urine. Microalbuminuria 
is better indicator than  Acute Physiological and Chronic Health Evaluation II 
(APACHE II) score and Sequential Organ Function Assesment score (SOFA 
score) in predicting vasopressor requirement and mortality. 
 
 This study was conducted at Institute of Internal Medicine, Madras Medical 
college and Rajev Gandhi Government General Hospital, Chennai to evaluate the 
degree of microalbuminuria in sepsis patients and whether it could predict 
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mortality in sepsis and also also to evaluate the corrulation of microalbuminuria 
and APACHE II Score.  
 After getting approval from ethical committee 50 patients presented with 
features of SIRS and suspected infection were included after fulfilling the 
exclutioncriteria.Urine for ACR was done on admission and at 24 hours of 
admission and APACHE II Score was calculated in the first 24 hours of admission. 
Patients presenting with features of SIRS and suspected infection were included in 
the study and after exclusion, a total of 50 patients were included in the study. 
Urine for ACR (Albumin and Creatinine Ratio) was done on admission  (ACR1) 
and at 24 hours (ACR2) of admission and APACHE II score calculated. 
1) Total 50 patients were included in the study, the mean age group of patients 
were 43.5 ± SD 15.8. Patients were distributed from age 16 to 85 years. 
2) Out of 50 patients 19 patients were females and 31 patients were males. Male 
patients constituted 62% and females 38%. 
3) 27  patients had all the 4 criteria of SIRS, and 19 patients had 3 criteria of SIRS 
and 4 patients had only 2 criteria of SIRS. 
4) Mortality in this study was 38%.  31 patients died out of total 50 patients and the 
mortality was more among male patients (62%) than among female patients and 
age was an independent predictor of mortality with mortality increasing linearly 
with age. 
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5) APACHE  II score ranged from 6 to 37. Mean  APACHE II score among 
survivors were 16.35 and among non survivors were 25.47 Non survivors has a 
higher APACHE II score compared to survivors. P value was statistically 
significant with p of < 0.0001. 
6) Mean Urine ACR 1 among survivors  was 74.06 μg/mg  and among non 
survivors164.53  and ACR 2 was 45.81 among survivors and 157.4 among non 
survivors.Both were statistically significant with p value of 0.0001 
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LIMITATIONS OF THE STUDY 
 
1) Sample size is small. 
2) Smoking and Hypertension etc ... could be independent cause of 
microalbuminuria. 
3) Patients with urological causes of sepsis were not included in the study group. 
4) Sepsis with pre-existing Chronic kidney disease could not be included in the 
study. 
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CONCLUSION 
 
• Presence of significant microalbuminuria at admission and persistence of 
microalbuminuria at 24 hrs of admission correlated well with mortality as 
comparable to APACHE II score.  
 
• Survival rate in patients with severe  sepsis can be improved by early 
institution of intensive therapy .  
 
• Microalbuminuria is an inexpensive rapid diagnostic as well as prognostic 
tool. 
 
• Hence microalbuminuria can be used as dynamic marker of sepsis. 
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 STUDY OF MICROALBUMINURIA IN SEPSIS WITH REFERENCE TO 
APACHE II SCORE 
Name : Patient ID No: 
Age/Sex :      Contact No: 
Occupation:                                                               Address: 
DOA:                                                                          
DOD: 
CHIEF COMPLAINTS: 
☐ Fever    ☐ Burning micturation 
☐ Breathlessness   ☐ swelling of legs/puffiness of  Face/Abdominal distention 
☐ Cough with expectoration  ☐ Decreased urine output 
☐ Chest pain  ☐ Altered sensorium 
☐ Yellowish discoloration of urine/eyes ☐Abdominal pain   ☐ Seizures 
☐☐ 
H/O PRESENTING COMPLAINTS: 
☐FEVER:☐BREATHLESSNESS 
Duration-                                                                 Duration- 
Low grade/High grade                                            Sudden onset/Insidious onset 
Continuous/Intermittent                                          Progression 
Chills/Rigor                                                            Grade- 
Associated with Bleeding-                                     Diurnal variation-   
manifestations/Myalgia/Joint pain                         PND/Orthopnoea 
                                                                                Aggravating/Relieving factor 
 
COUGH WITH/WITHOUTCHEST PAIN: 
EXPECTORATION:                                            Duration- 
Duration-                                                                 Site 
Sudden onset/Insidious onset                                  Sudden onset/Insidious onset                                                                    
Colour of the sputum                                               Type  
Blood stained/Not                                                    Radiation  
Amount/Smell                                                          Aggravating/Relieving factor 
 
ABDOMINAL PAIN:BURNING MICTURATION 
Duration-                                                                  Duration 
Site 
Sudden onset/Insidious onset 
Type                                                         YELLOWISH DISCOLOURATION                        
Radiation                                                                  OF URINE/EYES 
Aggravating/Relieving factor                                   Duration 
Associated with constipation/diarrhoea 
 
SWELLING OF LEGS/PUFFINESSFACEDECREASED URINE OUTPUT  /ABDOMINAL DISTENTION 
Duration                                                                    Duration 
Onset                                                                           Amount of urine output 
Progression 
 
ALTERED SENSORIUMHEAD ACHE 
Duration Duration-                 
Sudden onset/Insidious onset                                      Site                                                
                                                                                     Type   
                                                                                     Continuous/Intermittent                        
SEIZURES       Aggravating/Relieving factor                                                                                                                                                                          
No of episodes 
Type         
Duration of each episode                                               Associated with 
Post ictal confusion 
Trauma 
 
OTHERS                             
 
 
PAST HISTORY: 
☐DM        ☐Pulmonary TB☐ SHT☐ CAD/Heart disease☐ Kidney disease☐ CVA/TIA☐ Other Neurological disease                         
☐Surgeries☐Similar illness            ☐OTHERS 
 
TREATMENT H/O: 
DrugsNative medicine 
Others 
OBTETRIC H/O:FAMILY H/O: 
Pregnant – yes/no 
 
PERSONAL HISTORY: 
☐ Smoking                                                 ☐ Diet                      ☐ Sleep 
☐ Alcohol intake                                        ☐Substance abuse   ☐ Bowel/Bladder 
 
GENERAL EXAMINATION 
Consciousness/orientation 
Built/Nourishment 
Pallor/Icterus/Cyanosis/Clubbing/Lymphadenopathy/Pedal edema 
Skin rash/Skin ulcer                                                              
Pulse:          GCS: E-          V-         M- 
BP:                                              MAP:            
RR:           
SpO2: 
FiO2   RS: 
Temperature: 
Pupil                                                                             
DEM 
Neck stiffness 
 
SYSTEMIC EXAMINATION:                          
CVS:P/A: 
 
 
 
 
 
CNS: 
 
 
 
PROVISIONAL DIAGNOSIS: 
 
INVESTIGATIONS 
CBC: 
Total WBC count -  
                    DC – P -     L-    E-    B-   
Hb   - 
PCV   -                        ECG: 
ESR   - 
Platelet count - 
LFT:                                                                 CXR: 
Total bilirubin - 
Direct   - 
Indirect  - 
SGOT  -    USG ABDOMEN/KUB: 
SGPT   - 
ALP   - 
Total protein -           
Albumin  - 
Globulin  -                               URINE C/S: 
RFT: 
Random blood sugar- 
Blood Urea  -     
Serum Creatinine - 
Fasting blood sugar-    BLOOD C/S:  
Postprandial blood sugar-  
 
SERUM ELECTROLITES: 
Sodium  - 
Potassium  -    OTHERS: 
Chloride  - 
Bicarbonate  - 
 
            FiO2 - 
ABG: PaO2 - 
PCO2 - 
pH - 
A-aDO2= [FiO2 (713)-5/4(PCO2)] - PaO2 
Urine microalbumin:creatinine ratio (ACR-1)-within 6 hours = 
Urine microalbumin:creatinine ratio (ACR-2)-at 48 hours = 
APACHE II SCORE: 
A) 
Temp(rectal)  -                       Sr. Na          - 
     MAP             -                      Sr. K          - 
     HR       -                     Sr.creatinine- 
     RR          -                       PCV            - 
     Oxygenation    -                    WBC           - 
     Arterial pH      -                     GCS             - 
 
A)Total                            = 
B) Age points                   = 
C) Chronic health points= 
 
Total APACHE II SCORE=A+B+C= 
 
Predicted mortality: 
 
Urine microalbumin:creatinine ratio (ACR-1)-within 6 hours = 
Urine microalbumin:creatinine ratio (ACR-2)-at 24 hours      = 
 
Treatment and observations: 
 
 
 
 
Length of the hospital stay: 
Duration of mechanical ventilation: 
Outcome: 
Comments: 
 INFORMATION SHEET 
 
 
TITLE:“STUDY OF MICROALBUMINURIA IN SEPSIS WITH 
REFERENCE TO APACHE II SCORE” 
 
NAME OF THE INVESTIGATOR:Dr.PRABAHARAN.U 
 
STUDY CENTRE: Rajiv Gandhi Government General Hospital, Chennai-03. 
 
NAME OF THE PARTICIPANT:   AGE:  SEX: 
 
PURPOSE OF THE STUDY:The purpose of this study is to find out the 
correlation between the degree of microalbuminuria and severity of sepsis. 
 
STUDY DESIGN: Observational study 
 
STUDY PROCEDURE:We are selecting certain cases and if you are found 
eligible, after filling up the questionnaire and clinical examination along with 
routine blood investigations, blood samples will also be sent for some special 
investigations like arterial blood gas analysis and blood culture and sensitivity. 
Also two urine sample will be collected, one within 6 hours and another at 24 
hours of admission for analysis to calculate urine albumin : creatinine ratio. You 
will also undergo ECG, chest x ray (if needed), USG KUB/Abdomen (if needed) 
and lumbar puncture and CSF analysis (if needed). These tests and special studies 
do not affect your final report or management. 
 
POSSIBLE RISKS: No possible risks by means of this study. 
 
POSSIBLE BENEFITS:if we found the degree of microalbuminuria correlates 
with severity of sepsis we can use this simple test as a prognostic marker in sepsis. 
 
CONFIDENTIALITY OF THE INFORMATION OBTAINED FROM THE 
PATIENT: The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation resulting from 
the research, no personally identifiable information will be shared. 
 
DECISION TO PARTICIPATE IN THE STUDY:Taking part in this study is 
voluntary. You are free to decide whether to participate in this study or to 
withdraw at any time; your decision will not result in any loss of benefits to which 
you are otherwise entitled. 
 
RESULT OF THE STUDY: 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
 
 
 
                                                      Signature of the patient attenders 
 
 
 
 
Date: 
Place:                                                                   Signature of Investigator 
 
 
 
 
 
 
 
 
 
 
PATIENT CONSENT FORM 
 
Study Title : “Study of microalbuminuria in sepsis with reference 
to APACHE II score” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Name of the patient :  
Age/Sex :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained 
to me in my own language 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected.  
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that 
arise from this study.  
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and 
to immediately inform the study staff if I suffer from any deterioration 
in my health or wellbeing or any unexpected or unusual symptoms.  
I hereby consent to participate in this study.  
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological and biochemical tests.  
 
 
 
 
 
Signature/thumb impression 
Patient’s Name and Address:                                   Signature of Investigator 
                                                                                  Study Investigator’s Name: 
                                                                                   Dr.PRABAHARAN.U.
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1 SAROJA 70 Female 65429 1 0 1 1 1 0 0 1 0 0 1 6 12 5 0 17 103 58 + + + + 4 ACUTE MENINGOENCEPHALITIS Survived
2 MAHALAKSHMI 20 Female 68050 1 0 2 3 3 3 1 1 0 0 0 4 18 0 0 18 107 104 + + + + 4 SEPSIS,ARDS,MODS Death 
3 SELVARAJ 65 Male 68389 1 0 2 1 1 0 0 0 0 0 0 1 6 5 0 11 74 37 + + + - 3 LEFT THIGH ABSCESS Survived
4 VASANTHA 55 Female 68478 1 0 2 3 1 3 1 0 0 0 1 5 17 3 0 20 68 55 + + + + 4 
SHT,ACUTE 
MENINGOENCEPHALITIS Survived
5 MANIMALA 38 Female 69286 0 2 2 3 1 2 0 1 0 1 0 3 15 0 5 20 86 53 - + + - 2 
B/L CYSTIC LUNG 
DISEASE,SEPSIS Survived
6 KANNIAPPAN 40 Male 69963 1 4 3 3 3 4 1 1 1 1 0 12 34 0 0 34 224 201 + + + - 3 SEPSIS,ARDS,MODS Death 
7 THIRUMURUGAN 32 Male 69970 1 2 2 3 3 2 2 0 1 0 0 4 20 0 5 25 170 155 + + + + 4 
RVD POSITIVE,B/L 
PNEUMONIA,SEPSIS Death 
8 SAVITHRI 55 Female 70024 1 2 2 2 1 2 1 0 1 1 0 1 14 3 0 17 62 53 + + + - 3 LEFT LEG CELLULITIS,SEPSIS Survived
9 
SURYA 
NARAYANAVASAN 45 Male 71816 0 0 2 4 1 3 1 1 0 0 1 4 17 1 0 18 97 96 - + + + 3 
SCHIZOPHRENIA,ASPIRATION 
PNEUMONITIS,RESPIRATORY 
FAILURE Death 
10 
SHANMUGA 
LAKSHMI 57 female 73082 1 4 2 3 3 3 1 1 1 1 0 4 24 3 0 27 85 58 + + + + 4 
SEPSIS,ARDS,RESPIRATORY 
FAILURE Survived
11 VISWANATHAN 85 Male 73517 0 4 3 3 2 4 3 1 1 1 0 6 28 6 0 34 222 177 - + + + 3 
ACUTE MENINGO 
ENCEPHALITIS/SEPSIS/SEPTIC 
SHOCK Death 
12 VISHNU PRIYA 17 Male 73566 1 0 0 3 1 2 0 0 0 0 0 4 11 0 0 11 55 34 + + + - 3 
ATAXIA TELENGECTATIA,LEFT 
LOWER LOBE CONSOLIDATION Survived
13 PITCHAI RAJ 49 Male 73920 1 2 2 3 2 1 1   0 0 1 3 16 2 0 18 99 123 + + + + 4 
RUPTURED LIVER 
ABSCESS,SEPSIS Death 
14 GAJENDRAN 52 Male 75912 0 4 3 4 3 3 2 2 1 1 0 6 29 2 0 31 133 185 - + + - 2 
ASPIRATION 
PNEUMONITIS,SEPTIC 
SHOCK,RESPIRATORY FAILURE Death 
15 JEYAMMAL 60 Female 76969 1 4 2 1 3 0 0 0 1 1 2 3 18 3 0 21 47 46 + + + + 4 
RT NECROTISING 
PNEUMONIA,SEPTIC SHOCK Survived
16 SUBRAMIANI 45 Male 77323 1 0 2 3 2 3 1 1 0 0 0 4 17 2 0 19 85 33 + + + + 4 
CAD,RIGHT LOWER LOBE 
PNEUMINIA Survived
17 DHAMODHARAN 56 Male 80278 1 0 2 2 1 3 1 1 0 1 0 7 19 3 0 22 95 72 + + + + 4 ACUTE MENINGOENCEPHALITIS Survived
18 SUMITHRA 21 Female 80318 1 2 2 4 1 2 1 0 1 0 1 4 19 0 0 19 160 132 + + + + 4 SEPSIS,MODS Death 
19 KASI 60 Male 80497 0 4 3 4 3 3 1 1 0 1 0 7 27 3 5 35 225 208 - + + - 2 SEPSIS,ARDS Death 
20 SENTHAMARAI 50 Female 81441 1 2 2 1 0 0 0 0 0 0 0 1 7 2 0 9 42 18 + + + + 4 LT LL CELLULITIS,SEPSIS Survived
21 MAHESHWARI 45 Female 81764 1 2 2 3 3 2 0 0 0 1 1 3 18 2 0 20 84 58 + + + + 4 RHD,PNEUMONIA,SEPSIS Survived
22 VAITHESHWARAN 32 Male 81857 1 0 3 3 1 2 0 0 0 0 0 4 14 0 5 19 149 114 + + + - 3 
RVD ,ASPIRATION 
PNEUMONITIS,SEPSIS Death 
23 CHINNARAJ 24 Male 82756 1 4 2 3 1 4 1 1 1 1 2 5 26 0 0 26 55 64 + + + + 4 
RUPTURED LIVER 
ABSCESS,SEPSIS Survived
24 GRACE 26 Female 82774 1 2 2 3 3 2 1 0 0 0 0 7 21 0 0 21 112 143 + + + - 3 
SEPSIS,ARDS,RESPIRATORY 
FAILURE Death 
25 CHANDRASEKAR 51 Male 84658 0 0 2 1 3 0 0 0 0 0 0 1 7 2 5 14 92 33 - + + + 3 
RIGHT LOWER LOBE 
BRONCHECTASIS/SEPSIS Survived
26 ANU 28 Female 84726 1 4 2 2 1 3 2 1 1 1 0 4 22 0 5 27 76 68 + + + - 3 RVD POSITIVE,SEPSIS Survived
27 VENKADESAN 45 Male 84732 1 2 2 3 3 1 1 0 0 0 1 2 16 2 0 18 88 48 + + + + 4 
RIGHT LOWER LOBE 
PNEUMONIA Survived
28 VIVEK 18 Male 84800 1 2 0 1 0 0 0 0 0 1 1 0 6 0 0 6 62 30 + + + - 3 SEPSIS Survived
29 DEVARAJ 53 Male 84851 1 0 2 1 0 0 0 0 1 0 0 4 9 2 0 11 35 44 + + + + 4 
SHT,ACUTE 
MENINGOENCEPHALITIS Survived
30 MOHAMED ALI 50 Male 84954 0 2 2 1 1 0 0 0 0 0 0 1 7 2 0 9 87 27 - + + - 2 
RIGHT MIDDLE LOBE 
CONSOLIDATION Survived
31 CHINNATHAMBI 39 Male 85354 1 2 2 3 1 2 2 1 1 1 0 2 18 0 0 18 33 52 + + + - 3 
CHRONIC 
ALCOHOLIC,SEPSIS,SEPTIC 
ENCEPHALOPATHY Survived
32 
SHAHERTHA 
BEGAM 50 Female 85594 1 4 2 4 2 1 0 1 1 1 0 4 21 2 5 28 167 162 + + + + 4 
COPD,SECONDARY 
INFECTION,RESPIRATORY 
FAILURE,SEPTIC SHOCK Death 
33 GAJALAKSHMI 16 Female 85739 1 0 0 1 0 0 0 0 0 0 1 3 6 0 0 6 71 32 + + + + 4 ACUTE MENINGO ENCEPHALITIS Survived
34 SABASTEIN 56 Male 86659 1 2 2 3 2 2 0 1 0 0 0 4 17 3 0 20 156 150 + + + + 4 
SHT,OLD CVA,LIVER 
ABSCESS,SEPSIS Death 
35 RAJ 39 Male 87001 1 0 2 3 1 2 2 1 1 1 0 4 18 0 5 23 158 155 + + + - 3 DCLD,SEPSIS Death 
36 SULTHAN BASHA 30 Male 87730 1 4 2 2 2 3 2 0 0 1 0 10 27 0 0 27 158 158 + + + + 4 CSOM,CEREBELLAR ABSCESS Death 
37 RAMALINGAM 60 Male 87830 1 4 2 3 1 2 0 0 1 1 0 2 17 3 5 25 92 84 + + + + 4 
DCLD,LEFTLOWER LOBE 
CONSOLIDATION Survived
38 MUNUSAMY 53 Male 87835 1 2 2 1 0 0 0 0 0 0 1 3 10 2 0 12 89 35 + + + + 4 ACUTE MENINGOENCEPHALITIS Survived
39 VAIRAM 35 Male 87943 1 0 2 3 1 1 1 0 0 0 0 9 18 0 0 18 179 142 + + + - 3 
CHRONIC ALCOHOLIC,ACUTE 
MENINGOENCEPHALITIS Death 
40 THIYAGARAJAN 45 Male 88800 1 0 2 1 0 0 0 0 0 0 0 3 7 2 0 9 61 23 + + + - 3 ACUTE MENINGOENCEPHALITIS Survived
41 MADURAI 75 Male 88820 1 4 2 3 1 2 0 0 1 1 0 2 17 6 0 23 102 68 + + + + 4 LIVER ABSCESS Survived
42 PALANI 41 Male 88879 1 4 2 1 0 0 0 0 1 1 1 4 15 0 0 15 100 46 + + + + 4 
SHT,ACUTE NECROTISING 
PANCREATITIS,ASPIRATION 
PNEUMONITIS Survived
43 SRIDEVI 35 Female 88906 1 0 2 3 0 3 0 1 0 0 0 3 13 0 0 13 99 36 + + + - 3 ACUTE MENINGOENCEPHALITIS Survived
44 DILLI BASKAR 40 Male 89353 1 2 2 4 3 2 2 1 0 1 0 6 24 0 0 24 133 152 + + + + 4 
CHRONIC 
ALCOHOLIC,NECROTISING 
PNEUMONIA,SEPSIS Death 
45 ABDUL KAPOOR 55 Male 90420 1 2 2 2 3 4 0 2 0 1 2 3 22 3 5 30 88 80 + + + + 4 
COPD,RIGHT LOWER LOBE 
PNEUMONIA,SEPSIS Survived
46 SURESH 32 Male 90541 1 4 2 4 2 3 2 1 1 2 0 8 30 0 5 35 232 221 + + + - 3 
DCLD,PHT,B/L LL 
CELLULITIS,SEPSIS Death 
47 ANJALA 50 Female 90587 1 2 2 3 0 1 0 0 0 0 1 3 13 2 0 15 85 34 + + + + 4 ACUTE MENINGOENCEPHALITIS Survived
48 KARTHIKA 21 Female 91431 1 2 2 2 0 1 0 1 0 0 0 1 10 0 0 10 44 26 + + + - 3 PERI ANAL ABSCESS,SEPSIS Survived
49 DEVAKI 17 Female 91589 1 0 0 1 0 0 0 0 0 0 0 4 6 0 0 6 51 15 + + + - 3 ACUTE MENINGOENCEPHALITIS Survived
50 NIRMALA 42 Female 92150 1 4 3 4 3 3 2 2 1 2 1 6 32 0 5 37 245 221 + + + + 4 
DCLD,PHT,SEPSIS,REFRACTORY 
SEPTIC SHOCK Death 
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